Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

被引:20
作者
Choi, Peter [1 ]
Farouk, Mourad [2 ]
Manamley, Nick [3 ]
Addison, Janet [3 ]
机构
[1] John Hunter Hosp, Dept Nephrol, New Lambton Hts, NSW 2305, Australia
[2] Amgen Europe GmbH, CH-6301 Zug, Switzerland
[3] Amgen UK Ltd, Cambridge, England
关键词
Anemia; Chronic kidney disease; Darbepoetin alfa; Dose conversion; Erythropoiesis-stimulating agent; Hematology; Hemodialysis; Medication switching; Pegylated erythropoietin beta; Retrospective study; ANEMIA; AGENTS;
D O I
10.1007/s12325-013-0063-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observational study designed to estimate the population mean maintenance dose conversion ratio [DCR; dose ratio achieving comparable hemoglobin level (Hb) between two evaluation periods] in European hemodialysis patients whose treatment was switched from DA to PEG-Epo. Eligible patients had received hemodialysis for a parts per thousand yen12 months and DA for a parts per thousand yen7 months. Data were collected from 7 months before until 7 months after switching treatment. DCR was calculated for patients with Hb and ESA data available in both evaluation periods (EP; Months 1 and 2 were defined as the pre-switch EP, and Months 6 and 7 as the post-switch EP). Red blood cell transfusions pre- and post-switch were quantified. Of 302 patients enrolled, 206 had data available for DCR analysis. The geometric mean DCR was 1.17 (95% CI 1.05, 1.29). Regression analysis indicated a non-linear relationship between pre- and post-switch ESA doses; DCR decreased with increasing pre-switch DA dose. The geometric mean weekly ESA doses were 24.1 mu g DA in the pre-switch EP and 28.6 mu g PEG-Epo in the post-switch EP. Mean Hb was 11.5 g/dL in the pre-switch EP and 11.4 g/dL in the post-switch EP. There were 16 transfusions and 34 units transfused in the pre-switch period, versus 48 transfusions and 95 units transfused post-switch. Excluding patients receiving a transfusion within 90 days of or during either EP, the DCR was 1.21 (95% CI 1.09, 1.35). In these hemodialysis patients switched from DA to PEG-Epo the DCR was 1.17 and 1.21 after accounting for the effect of transfusions. The number of transfusions and units transfused increased approximately threefold from the pre-switch to the post-switch period.
引用
收藏
页码:1007 / 1017
页数:11
相关论文
共 13 条
[1]  
Aranesp, 2013, AR DARB ALF SUMM PRO
[2]   Association of kidney function with anemia - The Third National Health and Nutrition Examination Survey (1988-1994) [J].
Astor, BC ;
Muntner, P ;
Levin, A ;
Eustace, JA ;
Coresh, J .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (12) :1401-1408
[3]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[4]   Intravenous CERA maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study [J].
Canaud, Bernard ;
Mingardi, Giulio ;
Braun, Johann ;
Aljama, Pedro ;
Kerr, Peter G. ;
Locatelli, Francesco ;
Villa, Giuseppe ;
Van Vlem, Bruno ;
McMahon, Alan W. ;
Kerloeguen, Cecile ;
Beyer, Ulrich .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (11) :3654-3661
[5]   Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial [J].
Carrera, Fernando ;
Lok, Charmaine E. ;
de Francisco, Angel ;
Locatelli, Francesco ;
Mann, Johannes F. E. ;
Canaud, Bernard ;
Kerr, Peter G. ;
Macdougall, Iain C. ;
Besarab, Anatole ;
Villa, Giuseppe ;
Kazes, Isabelle ;
Van Vlem, Bruno ;
Jolly, Shivinder ;
Beyer, Ulrich ;
Dougherty, Frank C. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (12) :4009-4017
[6]   ANEMIA OF END-STAGE RENAL-DISEASE (ESRD) [J].
ESCHBACH, JW ;
ADAMSON, JW .
KIDNEY INTERNATIONAL, 1985, 28 (01) :1-5
[7]   Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease [J].
Hoerl, Walter H. .
DRUGS, 2013, 73 (02) :117-130
[8]   Anemia: An early complication of chronic renal insufficiency [J].
Kazmi, WH ;
Kausz, AT ;
Khan, S ;
Abichandani, R ;
Ruthazer, R ;
Obrador, GT ;
Pereira, BJG .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) :803-812
[9]  
Locatelli F., 2004, NEPHROL DIAL TRANSPL, V19, pii16
[10]   How important is transfusion avoidance in 2013? [J].
Macdougall, Iain C. ;
Obrador, Gregorio T. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (05) :1092-1099